Your trusted source for clear, analytical news.

Company

About Us Contact Us Authors Feedback Grievance

Legal

Terms of Service Privacy Policy Code of Business Cookie Policy Corrections Policy

© 2026AirNews. All Rights Reserved.

Indoco Remedies Net Profit Soars to ₹19.5 Crore, Shares Up 3.4% | AirNews.in

stocks

360 ONE Asset: Valuations 10% Below Long-Term Average Signal Equity Upside Dr Reddy's Q4 Revenue Up 7.7%, Shares Rise 3% as Biosimilar Hype Builds NTPC Q2 Earnings Forecast Up 20% Amid Rising Demand L&T Secures ₹10,000 Crore Dhaka Metro Orders, Stock Climbs 0.4%VA Tech Wabag Sees 8% Surge After Securing ₹1,000 Crore RIL Order Sona BLW Q2 Revenue Soars 35%, Stock Jumps 10%Ather Energy Q2 Profit Surges 822% to ₹1.26 Cr; Shares Rise 7%Transformers and Rectifiers Investment of ₹1,250 Cr Drives 6% Stock Surge Acutaas Chemicals Q2 EBITDA Surges 86%, Shares Rally 12%Indoco Remedies Net Profit Soars to ₹19.5 Crore, Shares Up 3.4%360 ONE Asset: Valuations 10% Below Long-Term Average Signal Equity Upside Dr Reddy's Q4 Revenue Up 7.7%, Shares Rise 3% as Biosimilar Hype Builds NTPC Q2 Earnings Forecast Up 20% Amid Rising Demand L&T Secures ₹10,000 Crore Dhaka Metro Orders, Stock Climbs 0.4%VA Tech Wabag Sees 8% Surge After Securing ₹1,000 Crore RIL Order Sona BLW Q2 Revenue Soars 35%, Stock Jumps 10%Ather Energy Q2 Profit Surges 822% to ₹1.26 Cr; Shares Rise 7%Transformers and Rectifiers Investment of ₹1,250 Cr Drives 6% Stock Surge Acutaas Chemicals Q2 EBITDA Surges 86%, Shares Rally 12%Indoco Remedies Net Profit Soars to ₹19.5 Crore, Shares Up 3.4%

Indoco Remedies Net Profit Soars to ₹19.5 Crore, Shares Up 3.4%

about 1 hour ago

Published: October 27, 2026

Indoco Remedies Net Profit Soars to ₹19.5 Crore, Shares Up 3.4%

Indoco Remedies posted Q2 FY27 net profit of ₹19.5 crore, turning a ₹9.2 crore loss a year earlier. Shares surged 3.42% to ₹227 on Tuesday, though the stock sits ~1% down for the day.

Indoco Remedies shares jumped 3.42% to ₹227 after announcing a net profit of ₹19.5 crore in Q2 FY27, reversing a ₹9.2 crore loss in the same quarter a year earlier.

Revenue climbed 7.4% YoY to ₹507 crore from ₹472 crore, while EBITDA rose 10% to ₹33 crore versus ₹30.2 crore a year ago, nudging the margin to 6.5% from 6.4%.

The turnaround follows two consecutive quarters of losses, marking the first profitable reporting period in 2025 and lifting investor confidence in the company’s pricing power.

Indoco will file Q3 FY27 results on Nov 15; analysts expect a modest growth in margins as the company expands its generic portfolio. The pharma sector remains mixed, with peers reporting similar or slightly higher margins.